Flagship Pioneering, LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Flagship Pioneering, LLC reported 5 stock positions worth $1.5 billion. Its top holding was Generate Biomedicines (GENB) at 68.7% of the portfolio, followed by Moderna (MRNA, 21.1%) and Sana Biotechnology (SANA, 5.7%). Its holdings were unchanged from Q1 2026.
- Most Recent 13F
- Q2 2026
- Location
- CAMBRIDGE, MA
- CIK
- 0001400240
- Portfolio Value
- $1.5B (Q2 2026)
- SEC Filing
- 0001193125-26-352122 ↗ filed Aug 14, 2026
Holdings Value
Holdings 5 stocks · $1.5B
| GENB Generate Biomedicines Inc. | 68.66% | 62,673,117 | $1.1B | No change |
| MRNA Moderna Inc. | 21.07% | 4,632,149 | $324.4M | No change |
| SANA Sana Biotechnology Inc. | 5.67% | 25,001,856 | $87.3M | No change |
| FHTX Foghorn Therapeutics Inc. | 4.02% | 12,674,120 | $61.8M | No change |
| MCRB Seres Therapeutics Inc. | 0.59% | 1,155,850 | $9.1M | No change |
Portfolio Sells Q1 2026 → Q2 2026
| None this quarter. | |||
Portfolio Buys Q1 2026 → Q2 2026
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 5 | $1.5B | GENB, MRNA, SANA, FHTX, MCRB |
| Q1 2026 | 5 | $1.2B | GENB, MRNA, SANA, FHTX, MCRB |
| Q4 2025 | 4 | $324.0M | MRNA, SANA, FHTX, MCRB |
| Q3 2025 | 4 | $292.6M | MRNA, SANA, FHTX, MCRB |
| Q2 2025 | 4 | $268.5M | MRNA, SANA, FHTX, MCRB |
| Q1 2025 | 4 | $235.8M | MRNA, FHTX, SANA, MCRB |
| Q4 2024 | 5 | $334.2M | MRNA, FHTX, SANA, OMGAQ, MCRB |
| Q3 2024 | 6 | $591.9M | MRNA, FHTX, SANA, OMGAQ, MCRB |
| Q2 2024 | 6 | $843.4M | MRNA, SANA, FHTX, OMGAQ, MCRB |
| Q1 2024 | 7 | $1.5B | MRNA, SANA, OMGAQ, FHTX, DNLI |